[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 239
86. Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, Abonour R, Cornetta K, Cripe LD: Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant; 2010 Aug;45(8):1300-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
  • A total of 50 consecutive patients (median age, 57.5 years) with AML (n=30) or myelodysplasia (MDS, n=20) underwent HLA matched related donor (MRD, n=27) or unrelated donor (MUD, n=23) peripheral blood hematopoietic cell transplantation after nonmyeloablative CY/fludarabine (Flu) conditioning.
  • MUD recipients were engrafted quickly (13.5 days) compared to MRD recipients (16 days) and relapsed/progressed less frequently (P=0.005).
  • Overall grade 3/4 acute GVHD (aGVHD) occurred in 26% in the absence of antecedent mucositis and was associated with chronic GVHD (cGVHD) and poor OS.
  • This study provides further evidence for prolonged DFS after CY/Flu MRD allotransplantation for AML/MDS, and extends the findings to older patients and those with unrelated donors.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cyclophosphamide / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Survival Analysis. Transplantation, Homologous. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Young Adult


87. Kameoka J, Horiuchi T, Miyamura K, Miura I, Okuda M, Nomura J, Hirokawa M, Sawada K, Sasaki T: [Acute monoblastic leukemia with tetrasomy 8]. Rinsho Ketsueki; 2006 Aug;47(8):770-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute monoblastic leukemia with tetrasomy 8].
  • Tetrasomy 8 is a rare chromosomal abnormality in acute leukemia, and it has recently been considered as a poor prognostic factor.
  • The patient was diagnosed as having AML (M5a), and treatment with daunorubicin (70 mg x 5 days) and cytosine arabinoside (150 mg x 7 days) resulted in a complete remission.
  • She relapsed four months later, however, with an extramedullary tumor in T12.
  • Her clinical course was almost uneventful except for a phlegmon in the right leg, but on day 49 a relapse occurred, and she died of acute renal failure on day 73.
  • This case strongly illustrates the characteristic of tetrasomy 8 as a poor prognostic factor in acute leukemia.
  • [MeSH-major] Aneuploidy. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Karyotyping. Leukemia, Monocytic, Acute / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Fatal Outcome. Female. Humans. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986717.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshò„ ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


88. Chevallier P, Hunault-Berger M, Larosa F, Dauriac C, Garand R, Harousseau JL: A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leuk Res; 2009 Aug;33(8):1124-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.
  • This was a phase II investigation of high-dose imatinib in 15 adult patients with relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia (AML).
  • While no activity was seen in this phase II trial, the findings of the study do not rule out efficacy in subsets of AML with imatinib-sensitive Kit mutations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Genes, abl. Leukemia, Myeloid, Acute / drug therapy. Piperazines / administration & dosage. Proto-Oncogene Proteins c-kit. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Aged. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990444.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


89. Zhang DH, Dai M, Zhou HS, Wang YY, Zhang L, Zhang L, Wang B, Cao WJ: [Monitoring CML28 mRNA levels in patients before and after HSCT by real-time quantitative RT-PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct;13(5):843-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to establish a SYBR Green I real-time quantitative RT-PCR method for investigating the correlation between CML28 mRNA expression levels and relapse of leukemia after allo-hematopoietic stem cell transplantation (HSCT).
  • Serial monitoring of CML28 mRNA levels by SYBR Green I real-time quantitative RT-PCR technique was performed in 14 patients, including 10 patients with CML and 3 patients with AML, 1 patient with Ph(+) ALL.
  • The CML28 was highly expressed in AML and CML-BP or AP.
  • 2 of them with low level (<2 x 10(-2)) survived without relapse, the other 2 case with high level (>2 x 10(-2)) relapsed within one year, 1 case died and 1 case received the second time HSCT, CML28 level decreased rapidly after HSCT, but still higher than 2 x 10(-2) and relapse has taken place.
  • The conclusions was made that CML28 mRNA level is obviously correlated with the development of leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277855.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / EXOSC5 protein, human; 0 / Organic Chemicals; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 163795-75-3 / SYBR Green I; EC 3.1.- / Exoribonucleases; EC 3.1.- / Exosome Multienzyme Ribonuclease Complex
  •  go-up   go-down


90. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, Perreau V, Coso D, Pigneux A, Vey N: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer; 2005 Nov 1;104(9):1931-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
  • BACKGROUND: Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC).
  • RESULTS: All patients engrafted had cumulative incidences of Gluksberg System Grade 2 acute and chronic graft-versus-host-disease (GVHD) of 24 (9-39%) and 64 (48-80%), respectively.
  • Three patients died from nonrelapse causes (NRD) (cumulative incidence: 9%, 95% confidence interval (CI): 0-19) and 6 relapsed (cumulative incidence: 18%, 95% CI: 5-31).
  • With a median follow-up of 18 months (range 7-52) after Allo-SCT, 26 patients are alive, of whom 24 remained in CR1 for a 2-year overall survival and leukemia-free survival (LFS) probabilities of 79 (range 61-90%) and 76 (range 59-87%), respectively.
  • CONCLUSIONS: We conclude that the sequential combination of intensive chemotherapy and allogeneic immunotherapy might offer relatively low NRD and leukemia relapse rates even in high-risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pilot Projects. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16178004.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Bang SM, Ahn JY, Park J, Park SH, Park J, Cho EK, Shin DB, Lee JH, Yoo SJ, Jeon IS, Kim YK, Kim HJ, Kim HN, Lee IK, Kang HJ, Shin HY, Ahn HS: Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. J Korean Med Sci; 2008 Oct;23(5):833-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia.
  • FLT3 mutations are common genetic changes, and are reported to have prognostic significance in acute myeloid leukemia (AML).
  • The FLT3 internal tandem duplication (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD) were analyzed by polymerase chain reaction (PCR) in the genomic DNA of Korean patients with AML at diagnosis and during follow-up.
  • There were 226 patients with AML enrolled between March 1996 and August 2005.
  • When compared to Western and other Asian patients with AML, Korean patients had a lower frequency by about two-thirds of ITD and TKD.
  • Among the non-M3 cases (N=203), the patients with an ITD had a significantly shorter event-free survival when compared with those without an ITD (p=0.0079).
  • Among 54 relapsed patients, 9 patients had the FLT3 ITD at diagnosis.
  • One patient, among 45 patients who relapsed, had a negative baseline ITD but acquired a de novo ITD at relapse.
  • Therefore, effective therapy with FLT3 targeting agents may improve the prognosis of non-M3 AML patients with the FLT3 mutation.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / genetics. Mutation. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Korea. Male. Middle Aged. Prognosis. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):7-13 [15604885.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):196-202 [16029447.001]
  • [Cites] Leuk Res. 2005 Dec;29(12):1393-8 [15996732.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1788-93 [17064989.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):983-8 [11442493.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1699-704 [12200684.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2387-92 [12239146.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3423-5 [12384447.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1541-7 [12400596.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):2027-9 [12481903.001]
  • [Cites] Hematol J. 2002;3(6):283-9 [12522450.001]
  • [Cites] Haematologica. 2003 Jan;88(1):19-24 [12551822.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Leuk Res. 2004 Oct;28(10):1069-74 [15289019.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1605-9 [9324277.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Br J Haematol. 1999 Mar;104(4):659-64 [10192423.001]
  • [Cites] Leuk Res. 2005 Jun;29(6):617-23 [15863200.001]
  • (PMID = 18955790.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2580007
  •  go-up   go-down


92. Yamaguchi Y, Usui N, Dobashi N, Yano S, Yahagi Y, Takei Y, Sugiyama K, Ogasawara Y, Saito T, Minami J, Kobayashi T, Katsube A, Kamiyama Y, Machishima T, Morikawa N, Otsubo H, Kaito K, Asai O, Aiba K: Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia. Gan To Kagaku Ryoho; 2009 Jul;36(7):1105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia.
  • We conducted to evaluate the efficacy and toxicity of GO in our patients with relapsed or refractory AML retrospectively.
  • PATIENTS AND METHODS: Data were collected between March 1, 2000, and March 1, 2006, on 10 patients with relapsed or refractory AML(excluding FAB: M3).
  • CONCLUSION: GO is a valuable new treatment option for relapsed or refractory AML patients, however, the benefit from single agent appears insufficient.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Drug-Induced Liver Injury. Female. Humans. Hypersensitivity / etiology. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620797.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


93. Thomas X, Dombret H: Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia. Hematology; 2007 Feb;12(1):15-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
  • Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of acute myeloid leukemia.
  • Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome.
  • Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory AML or used as post-remission therapy, and compare them with those from other types of regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Animals. Antimetabolites, Antineoplastic / administration & dosage. Bone Marrow Diseases / chemically induced. Cell Cycle / drug effects. Child. Cytarabine / pharmacology. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Flavonoids / administration & dosage. Flavonoids / pharmacology. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / pharmacology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Middle Aged. Piperidines / administration & dosage. Piperidines / pharmacology. Premedication. Prognosis. Rats. Remission Induction / methods. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364988.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 45AD6X575G / alvocidib; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 127
  •  go-up   go-down


9
Advertisement
4. Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, Barrett AJ: Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant; 2010 Sep;16(9):1257-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.
  • Elimination of malignant cells through a graft-versus-leukemia (GVL) effect involves donor T and natural killer (NK) cells, but their relative contribution to this process is poorly defined.
  • Univariate and multivariate analysis of transplant-related risk factors and KIR genotyping was performed to identify independent variables predictive of outcome for different forms of leukemia.
  • Further to confirming known predictive factors for TRM and survival (CD34 cell dose, patient age, disease stage), statistical analysis revealed that 3 donor B haplotype KIR genes, 2DL5A, 2DS1, and 3DS1, were associated with significantly less relapse in patients with acute myelogenous leukemia (AML) (13% versus 57%) but not in patients with other myelogenous or lymphoid malignancies.
  • AML patients receiving SCT from donors with these KIR genes relapsed 4 times less frequently than patients transplanted from donors with other KIR genotypes.
  • These findings suggest specific, genetically determined, interactions between NK cells and AML cells that facilitate the GVL effect, and have implications for donor selection for AML patients.
  • [MeSH-major] HLA Antigens / immunology. Hematologic Neoplasms / genetics. Hematologic Neoplasms / therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Receptors, KIR / genetics. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cohort Studies. Female. Histocompatibility Testing. Humans. Male. Middle Aged. Multivariate Analysis. Risk Factors. Siblings. Tissue Donors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Transplantation. 1999 Dec 15;68(11):1784-9 [10609957.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Tissue Antigens. 2003 May;61(5):403-7 [12753660.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):874-85 [12786798.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1865-70 [12970788.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):217-24 [15059145.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1835-8 [15457184.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1688-95 [16131570.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1024-30 [17060849.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2145-52 [17673900.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1216-23 [17889359.001]
  • [Cites] Bone Marrow Transplant. 2008 Feb;41(3):245-52 [17952129.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1852-8 [18945751.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):951-6 [11753550.001]
  • (PMID = 20302958.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA HL006105-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Receptors, KIR
  • [Other-IDs] NLM/ NIHMS207885; NLM/ PMC3801172
  •  go-up   go-down


95. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM: A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res; 2009 Nov 1;15(21):6732-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
  • PURPOSE: Inhibiting mammalian target of rapamycin (mTOR) signaling in acute myelogenous leukemia (AML) blasts and leukemic stem cells may enhance their sensitivity to cytotoxic agents.
  • We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy.
  • EXPERIMENTAL DESIGN: We performed a phase I dose escalation study of sirolimus with the chemotherapy regimen MEC (mitoxantrone, etoposide, and cytarabine) in patients with relapsed, refractory, or untreated secondary AML.
  • Future studies are planned with different schedules to clarify the clinical and biochemical effects of sirolimus in AML and to determine whether target inhibition predicts chemotherapy response.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Sirolimus / administration & dosage
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Etoposide / therapeutic use. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / therapeutic use. Middle Aged. Protein Kinases / metabolism. Recurrence. Signal Transduction. TOR Serine-Threonine Kinases


96. Chowdhury S, Seropian S, Marks PW: Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol; 2009 Sep;84(9):599-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
  • Salvage chemotherapy for patients with relapsed or refractory acute myeloid leukemia (AML) is generally associated with a low-response rate and significant nonhematologic toxicity.
  • Both decitabine and gemtuzumab ozogamicin have activity in AML as single agents and can be administered sequentially with potential synergy due to their toxicity profiles.
  • Twelve patients with AML, who had received a median of three prior regimens (range 1-6), were treated with decitabine 20 mg/m(2) on days 1 through 5 followed by gemtuzumab ozogamicin 3 mg/m(2) on days 6, 9, and 12.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Azacitidine / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650144.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


97. Xu J, Xu CG, Liu T, Xiang B, Chang H, He C: [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan;40(1):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
  • OBJECTIVE: To evaluate the effectiveness and toxicity of the regimen combined homoharringtonine, low-dose cytarabine with G-CSF or GM-CSF (HAG regimen) in treating patients with relapsed or refractory AML, geriatric AML and advanced myelodysplastic syndromes (MDS).
  • METHODS: Forty patients with AML or advanced MDS were treated with HAG regimen for remission induction and consolidation therapy.
  • Results 20 of them (50%) achieved complete remission (CR), including 46.2% patients with relapsed or refractory AML, 60% elderly patients with primary AML who were either untreated or treated with only one course of induction therapy previously, and 66.7% patients with MDS-RAEB.
  • Non-hematologic adverse effects were minimal.
  • It seems promising for the treatment of relapsed or refractory AML, geriatric AML and advanced MDS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Female. Follow-Up Studies. Harringtonines / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Young Adult


98. Murase K, Iyama S, Sato T, Takimoto R, Kobune M, Kato J: [Therapeutic results in patients with biphenotypic acute leukemia at Sapporo Medical University Hospital]. Gan To Kagaku Ryoho; 2010 Oct;37(10):2011-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results in patients with biphenotypic acute leukemia at Sapporo Medical University Hospital].
  • We reviewed the results of 6 patients with biphenotypic acute leukemia (BAL) which the diagnostic standard of the European Group for the Immunological Characterization of Leukemia (EGIL) at Sapporo Medical University Hospital between 2006 and 2008.
  • Among them, 4 were B lymphoid and myeloid, 2 were T lymphoid and myeloid, and one was T/B lymphoid.
  • Two of 4 patients did not attain complete remission, and two relapsed after first treatment with acute myeloblastic leukemia (AML) protocol.
  • On the other hand, two showed complete remission after the acute lymphoblastic leukemia (ALL) protocol.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Hospitals, University. Humans. Japan. Male. Middle Aged. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Wang YL, Wang T, Xu F, Gang Y, Wang J: [Analysis of DEK-CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr;14(2):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of DEK-CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation].
  • This study was aimed to explore the relationship of 6; 9 chromosome translocation with DEK-CAN fusion gene expression in patients with acute myeloid leukemia (AML) and its clinical significance.
  • Chromosome specimens were prepared by routine method after short-term culture of bone marrow cells; karyotype analysis was performed by R banding technique; the expression of fusion gene DEK-CAN was analyzed by RT-nested-PCR in mononuclear cells of bone marrow or peripheral blood of 4 AML patients, for 3 patients received allo-BMT out of 4 patients the dynamic follow-up was performed.
  • q34) was confirmed by chromosome karyotype analysis in the four AML patients.
  • The DEK-CAN fusion gene was found during in all four de novo, relapsed and CR patients (100%).
  • And the expression of DEK-CAN fusion gene enhanced apparently in de novo and relapsed patients, and weakened in CR patient.
  • Clinical data showed 2 patients relapsed and died after CR for 1-24 months; the other two patients received allo-BMT got CR and still survive.
  • It is concluded that DEK-CAN fusion gene is the molecular basis in pathogenesis of AML.
  • The detection of DEK-CAN fusion gene is significant for diagnosis of AML, evaluation of curative effect, and predication of prognosis.

  • Genetic Alliance. consumer health - Chromosome 9.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638187.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DEK-CAN fusion protein, recombinant; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


100. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M: Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia; 2006 Feb;20(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
  • Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear.
  • Analysis of relapsed cases (14/125) indicated that an abnormal increase or decrease in WT1 expression was associated with a significantly increased risk of relapse (P=0.0006), and this prognostic impact of WT1 was independent of other main risk factors (P=0.0012).
  • In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / genetics






Advertisement